NASDAQ:SHPG Shire (SHPG) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free SHPG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$179.20▼$179.2050-Day Range$179.20▼$179.2052-Week Range$123.73▼$182.47VolumeN/AAverage Volume2.21 million shsMarket Capitalization$54.71 billionP/E Ratio11.83Dividend Yield0.19%Price TargetN/A Stock AnalysisStock Analysis Get Shire alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Shire Stock (NASDAQ:SHPG)Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. SHPG Stock News HeadlinesOctober 15, 2023 | investing.comSHPG Historical DataMarch 30, 2023 | thestreet.comShire Stock Hits New 52-Week High (SHPG)October 19, 2022 | bbc.comEthiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBCOctober 18, 2022 | bbc.comEthiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBCOctober 18, 2022 | news.yahoo.comEthiopia civil war: Federal army seizes strategic city of Shire - Yahoo NewsOctober 17, 2022 | washingtonpost.comEthiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington PostSeptember 25, 2022 | dailymail.co.ukMum saves toddler with CPR in Sydney's Hills Shire: Triple-0 call revealed: Police Defibrillators - Daily MailSeptember 15, 2022 | cbsnews.com"Hobbit home" up for sale in River Falls, Wisconsin - CBS NewsSeptember 10, 2022 | npr.orgFresh Air Weekend: Tennis great John McEnroe; Musician Amanda Shires - NPRSeptember 10, 2022 | npr.orgBest Of: John McEnroe / Amanda Shires : Fresh Air - NPRSeptember 7, 2022 | npr.orgAmanda Shires : Fresh Air - NPRSeptember 5, 2022 | theguardian.comMLB’s Art Shires: hitter, peacock, boaster, boxer and accused killer - The GuardianSeptember 1, 2022 | countrystandardtime.comAmanda Shires - Take It Like A Man - Country Standard TimeAugust 10, 2022 | theguardian.comDreaming shires: how East Yorkshire shaped Tolkien’s Middle-earth fantasy - The GuardianAugust 3, 2022 | npr.orgOn 'Take It Like a Man,' Amanda Shires takes aim for the heavens - NPRJuly 29, 2022 | theguardian.comAmanda Shires: Take It Like a Man review – reimagining country strong - The GuardianJuly 21, 2022 | nytimes.comAmanda Shires Isn’t Letting Nashville, or Her Marriage, Off the Hook - The New York TimesJuly 18, 2022 | dailymail.co.ukCat ban in Australia: Bass Coast Shire near Melbourne to fine pet owners if feline is outdoors - Daily MailJuly 17, 2022 | dailymail.co.ukNathan Brown lists $1.62million waterfront home in Sydney for sale - Daily MailJune 23, 2022 | yahoo.comCountry singer Amanda Shires explains why she told her abortion story: 'It's part of my character to speak up' - Yahoo LifeJune 17, 2022 | dallasnews.comRichardson retail and office center is latest commercial property sale - The Dallas Morning NewsMay 26, 2022 | dailymail.co.uk'Flood refugee' races to spruce up Scott Morrison's Shire home as he leaves Kirriblli House - Daily MailMay 10, 2022 | bizjournals.comIgnite Entertainment opens Shires' Cafe downtown at City Club Apartments - Cincinnati Business Courier - The Business JournalsApril 26, 2022 | law360.com2nd Circ. Affirms Shire Sanctions In Pharma IP Fight - Law360April 11, 2022 | afr.comSydney property: “There's money in the shire, it's crazy”, says agent who just sold a Cronulla home with no water views for $4.9 million - The Australian Financial ReviewSee More Headlines Receive SHPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/26/2018Today6/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPG CUSIPN/A CIK936402 Webwww.shire.com Phone353-1609-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$15.15 Trailing P/E Ratio11.83 Forward P/E Ratio11.88 P/E Growth1.54Net Income$4.27 billion Net Margins30.63% Pretax MarginN/A Return on Equity12.70% Return on Assets7.06% Debt Debt-to-Equity Ratio0.36 Current Ratio0.92 Quick Ratio0.51 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.61 Cash Flow$22.71 per share Price / Cash Flow7.89 Book Value$119.43 per share Price / Book1.50Miscellaneous Outstanding Shares305,280,000Free FloatN/AMarket Cap$54.71 billion OptionableOptionable Beta0.87 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Flemming Ornskov M.P.H. (Age 60)MBA, M.D., MPH, CEO, MD & Exec. Director Mr. Thomas J. W. Dittrich (Age 54)CFO & Director Gisele DionChief Accounting OfficerMr. Matthew Walker (Age 54)Head of Technical Operations Dr. Andreas Busch Ph.D. (Age 55)Head of R&D and Chief Scientific Officer Key CompetitorsNovartisNYSE:NVSAbbott LaboratoriesNYSE:ABTPfizerNYSE:PFESanofiNASDAQ:SNYVertex PharmaceuticalsNASDAQ:VRTXView All Competitors Should I Buy Shire Stock? SHPG Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Shire plc: Shire plc has shown consistent revenue growth over the past few quarters, indicating a strong financial performance. The company recently announced a strategic partnership that is expected to boost its market presence and potentially increase profitability. Shire plc's latest product, Xyrem XR, has received positive feedback from the market, potentially driving future revenue growth. Analysts predict a bullish trend for Shire plc's stock price in the upcoming quarters, making it a potentially lucrative investment opportunity. With a diversified product portfolio and global reach, Shire plc is well-positioned to capitalize on emerging market opportunities. Cons Investors should be bearish about investing in Shire plc for these reasons: Shire plc's debt-to-equity ratio has been increasing steadily, potentially indicating financial risk and impacting shareholder returns. The company faces increasing competition in the pharmaceutical industry, which could lead to pricing pressures and impact profit margins. Recent regulatory changes in key markets may pose challenges for Shire plc's product approvals and market access, affecting revenue streams. Market volatility and economic uncertainties could impact Shire plc's stock price, leading to short-term fluctuations and potential investor concerns. Analysts have raised concerns about Shire plc's dividend payout ratio, suggesting a need for careful monitoring of dividend sustainability and future growth prospects. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 30, 2024. Please send any questions or comments about these Shire pros and cons to contact@marketbeat.com. SHPG Stock Analysis - Frequently Asked Questions How were Shire's earnings last quarter? Shire plc (NASDAQ:SHPG) posted its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 30.63% and a trailing twelve-month return on equity of 12.70%. The business's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.63 earnings per share. Is Shire a good dividend stock? Shire (NASDAQ:SHPG) pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.19%. The dividend payout ratio is 2.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SHPG will have a dividend payout ratio of 2.15% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for SHPG. What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE), Starbucks (SBUX) and Exxon Mobil (XOM). This page (NASDAQ:SHPG) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
